BrainStorm’s ALS Treatment NurOwn, Filed Over Protest, Will Get US FDA Panel Review

 
• By Sue Sutter
Sailing
Will the FDA's current regulatory flexibility in ALS serve as a tailwind for NurOwn's approval? • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers